Journal of Critical Care
Volume 24, Issue 1 , Pages 43-49 , March 2009

Clinical implications of new neuromuscular concepts and agents: So long, neostigmine! So long, sux!

References 

  1. Bowman W.C., Rand M.J. Peripheral autonomic cholinergic mechanisms; 1980. Chapter 10, textbook of pharmacology, 2nd ed., Oxford Black Well Scientific Publications, London, Edinburgh, Boston, Melbourne, Paris, Berlin, Vienna.
  2. Lee C. Succinylcholine: its past, present, and future. In:  Katz RL editors. Muscle relaxants, basic and clinical aspects. Orlando: Grune & Stratton; 1984;p. 69–85
  3. Foldes FF, McNall PG, Borrego-Hinojosa JM. Succinylcholine: a new approach to muscular relaxation in anesthesiology. N Engl J Med. 1952;247:596–600
  4. Lee C, Jahr JS, Candiotti KA, et al: Reversal of profound neuromuscular block by sugammadex administered 3 minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. (personal information, manuscript in preparation, data on file)
  5. Durant NN, Nguyen N, Lee C, et al. A comparison of 3,4-diaminopyridine and 4-aminopyridine in the anaesthetized cat. Eur J Pharmacol. 1982;84-3:215–219
  6. Benumof JL, Dagg R, Benumof R. Critical hemoglobin desaturation will occur before return to an unparalyzed state following 1 mg/kg intravenous succinylcholine. Anesthesiology. 1997;87:979–982
  7. Savarese JJ, Ginsburg S, Lee C, et al. The pharmacology of new short-acting nondepolarizing ester neuromuscular blocking agents: clinical implications. Anesth Analg. 1973;52-6:982–988
  8. Gyermek L, Lee C, Cho YM, et al. Neuromuscular pharmacology of TAAC3, a new nondepolarizing muscle relaxant with rapid onset and ultrashort duration of action. Anesth Analg. 2002;94-4:879–885
  9. Boros EE, Bigham EC, Boswell GE, et al. Bis- and mixed-tetrahydroisoquinolinium chlorofumarates: new ultra–short-acting nondepolarizing neuromuscular blockers. J Med Chem. 1999;42:206–209
  10. Belmont MR, Lien CA, Tjan J, et al. Clinical pharmacology of GW280430A in humans. Anesthesiology. 2004;100-4:768–773
  11. Katz RL. A nerve stimulator for the continuous monitoring of muscle relaxant action. Anesthesiology. 1969;26-6:832–833
  12. Lee CM. Train-of-4 quantitation of competitive neuromuscular block. Anesth Analg. 1975;54-5:649–653
  13. Katz RL. Clinical neuromuscular pharmacology of pancuronium. Anesthesiology. 1971;34-6:550–556
  14. Kopman AF, Klewicka MM, Kopman DJ, et al. Molar potency is predictive of the speed of onset of neuromuscular block for agents of intermediate, short, and ultrashort duration. Anesthesiology. 1999;90:425–431

☆ The authors have in the past received supports for their neuromuscular researches from various sponsors including Organon, USA, Inc, now a part of Schering-Plough Corporation, owner of sugammadex. One author (CL) is coprincipal investigator and coinventor of the TAAC3 series of compounds (now deactivated) cited in the text as reference 8, which was in the past sponsored in part by said sponsor. He is also principal investigator of a multicenter study on sugammadex, cited as reference 4, which was also sponsored by the same sponsor.

PII: S0883-9441(08)00191-3

doi: 10.1016/j.jcrc.2008.08.009

Journal of Critical Care
Volume 24, Issue 1 , Pages 43-49 , March 2009

Article Tools